IPCA Laboratories is currently trading at Rs. 621.00, up by 1.50 points or 0.24% from its previous closing of Rs. 619.50 on the BSE.
The scrip opened at Rs. 622.00 and has touched a high and low of Rs. 622.50 and Rs. 618.00 respectively. So far 2057 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 708.00 on 11-Jul-2013 and a 52 week low of Rs. 401.10 on 08-Nov-2012.
Last one week high and low of the scrip stood at Rs. 641.95 and Rs. 610.00 respectively. The current market cap of the company is Rs. 7836.96 crore.
The promoters holding in the company stood at 45.89% while Institutions and Non-Institutions held 36.46% and 17.65% respectively.
Credit rating agency, CRISIL has reaffirmed AA rating to IPCA Laboratories’ long term bank facilities worth Rs 1182.50 crore. The company has received the rating reaffirmation on the back of its well-diversified business risk profile (across therapeutic segments and geographies), established position in the formulations segment both, in domestic and international market, and integrated operations.
IPCA is one of India’s largest suppliers of bulk drugs, such as atenolol (anti-hypertensive), chloroquine and artemisinin derivatives (anti-malarial), furosemide (diuretic), and pyrantel salts (anthelmintic).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: